Leucemia Mielóide Aguda t(8;21) após tratamento de hipertiroidismo com iodo radioativo: Leucemia secundária?

AUTOR(ES)

Bahia, Daniella M.M., Chauffaille, Maria L.F., Romeo, Maura S., Dias-Silva, Magnus R., Kerbauy, José

FONTE

Revista Brasileira de Hematologia e Hemoterapia

DATA DE PUBLICAÇÃO

2002-04

RESUMO

Acute leukemia following treatment with Iodine131 is a rare event. The possible carcinogenic effect of Iodine131 is still not clear and a large series of cases did not show an increased incidence of cancer. A case of AML t(8;21), three years after Iodine131 treatment for hyperthyroidism, is reported. Secondary AML with t(8;21) is described following exposure to drugs that target topoisomerase II and radiotherapy. The controversial potential of Iodine131 as a leukemogenic agent and the fact that t(8;21) is also found in de-novo AML, emphasize the problem in establishing a relationship between these events although this potential can not be ruled out.

Documentos Relacionados

• Leucemia mielóide aguda t(8;21): freqüência em pacientes brasileiros
• Translocação t(8;21)(q22;q22) em Leucemia Mielóide Aguda
• Leucemia mielóide aguda com t(8;21)(q22;q22) precedido de sarcoma granulocítico na mama
• Leucemia mielóide aguda-M0 com t(4;11) (q21;q23) após tratamento para sarcoma de Ewing com o protocolo EW92
• Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia